Age-Related Macular Degeneration (AMD) Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):–

https://shorturl.at/D5SPf

The Global Age-Related Macular Degeneration Market reached US$ 13.10 billion in 2023 and is expected to reach US$ 20.60 billion by 2031, growing at a CAGR of 5.82% during the forecast period 2024-2031.  

List of the Key Players in the  Age-Related Macular Degeneration (AMD) Market:

F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., Novartis AG, Apellis Pharmaceuticals, Inc., Astellas Pharma Inc., Biocon, Samsung Bioepis., Bausch + Lomb., Alcon Inc., Nature Made and among others.

Emerging Players

The emerging players in the age-related macular degeneration (AMD) market include Almirall, S.A, Aclaris Therapeutics Inc, Kiniksa Pharmaceuticals, Cara Therapeutics, VYNE Therapeutic and among others.

Industry Development:

In October 2024, Ocular Therapeutix, Inc. announced an accelerated timeline for the SOL-1 Phase 3 registrational clinical trial of AXPAXLI for wet age-related macular degeneration (wet AMD). The company now anticipates full enrollment and patient randomization by the end of 2024, significantly ahead of its initial target of Q1 2025. As a result, topline data from the SOL-1 trial are expected in Q4 2025.

In March 2024, Roche Pharma India expanded into the ophthalmology sector with the launch of Vabysmo (faricimab), a breakthrough treatment for neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME).

Growth Forecast Projected:

The Global  Age-Related Macular Degeneration (AMD) Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Segment Covered in the  Age-Related Macular Degeneration (AMD) Market:

By Type: Dry AMD, Wet AMD

By Treatment: Anti-VEGF Drugs, AREDS2 Supplements, Photodynamic Therapy, Others

By Patient Type: Male, Female

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com 
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com